Cencora gets a buy rating, agreeing with today's consensus from Wall St. The sector and macro environment points to continued demand for the healthcare supplies and niche specialty drugs Cencora can distribute. Future share price targets point to significant potential upside over 3 years, justifying a buy despite the stock trading above average now.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Cencora (COR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Medical Distribution Industry | Healthcare Sector | Dr. Robert P. Mauch Ph.D., PharmD CEO | NYSE Exchange | US03073E1055 ISIN |
United States Country | 46,000 Employees | 14 Feb 2025 Last Dividend | 16 Jun 2009 Last Split | - IPO Date |
Cencora, Inc., previously known as AmerisourceBergen Corporation, represents a cornerstone in the pharmaceutical distribution industry. Established in 2001 and headquartered in Conshohocken, Pennsylvania, the company specializes in sourcing and distributing pharmaceutical products across various markets. Its operation spans a comprehensive array of services targeted at facilitating the accessibility and distribution of pharmaceuticals, healthcare products, and related services. Cencora's business operations are segmented into U.S. Healthcare Solutions and International Healthcare Solutions, each catering to a diverse range of customers and needs within the healthcare and pharmaceutical sectors.
U.S. Healthcare Solutions:
International Healthcare Solutions: